文献速递重症综合管理与镇静镇痛

咪达唑仑序贯右美托咪定用于长期镇静可能缩短特定危重机械通气患者的撤机时间:一项随机对照研究

Sequential use of midazolam and dexmedetomidine for long-term sedation may reduce weaning time in selected critically ill, mechanically ventilated patients: a randomized controlled study.
PubMed 文献 · Crit Care · 2022-05-03
一句话结论在通过30分钟SBT但仍需镇静的危重机械通气患者中,咪达唑仑序贯右美托咪定较单用咪达唑仑缩短撤机时间并降低谵妄发生率。

这项单中心随机对照研究纳入252例预计机械通气≥72小时、已通过SBT安全筛查并完成30分钟SBT但仍需镇静的危重成人患者,随机分为咪达唑仑序贯右美托咪定组(M-D)、咪达唑仑序贯丙泊酚组(M-P)和单用咪达唑仑组(M),镇静目标RASS -2至0。M-D组较M-P组和M组恢复更早、拔管更快、目标镇静达标时间比例更高(均P<0.001)。M-D组较M组撤机时间更短(25.0 h vs 49.0 h;HR 1.47,95%CI 1.05至2.06;P=0.025),谵妄发生率更低(19.5% vs 43.8%,P=0.002)。三组不良事件无显著差异(均P>0.05)。作者认为咪达唑仑序贯右美托咪定是长期镇静有效且安全的策略。

要点

  • M-D组撤机时间25.0 h,短于M组的49.0 h(HR 1.47,95%CI 1.05至2.06;P=0.025)。
  • M-D组谵妄发生率19.5%,低于M组的43.8%(P=0.002)。
  • M-D组恢复、拔管及目标镇静达标时间比例均优于M-P组和M组(均P<0.001)。
  • M-P组恢复、拔管(均P<0.001)及撤机时间(P=0.048)短于M组,但镇静药物采购成本高于其他两组(均P<0.001)。
  • 三组不良事件无显著差异(均P>0.05)。

适用人群与场景

  • 三级学术医疗中心内科和外科ICU的危重机械通气成人患者,预计机械通气≥72小时,正在接受咪达唑仑镇静。
  • 已通过自主呼吸试验(SBT)安全筛查、完成30分钟SBT且无拔管指征、仍需要镇静的患者。

诊断标准与关键阈值

  • SBT安全筛查通过后行30分钟SBT,无拔管指征且仍需镇静者纳入。
  • 镇静目标为RASS -2至0,镇静药按目标滴定。

处置流程与药物剂量

  • M-D组:将咪达唑仑更换为右美托咪定,按RASS -2至0滴定。
  • M-P组:将咪达唑仑更换为丙泊酚,按RASS -2至0滴定。
  • M组:单用咪达唑仑镇静,按RASS -2至0滴定。

研究设计与关键结果

  • 单中心随机对照研究,纳入252例危重机械通气成人患者,随机分为M-D组、M-P组和M组。
  • M-D组较M-P组和M组恢复更早、拔管更快、目标镇静达标时间比例更高(均P<0.001)。
  • M-D组撤机时间25.0 h vs M组49.0 h(HR 1.47,95%CI 1.05至2.06;P=0.025)。
  • M-D组谵妄发生率19.5% vs M组43.8%(P=0.002)。
  • M-P组恢复(P<0.001)、拔管(P<0.001)和撤机时间(P=0.048)短于M组;镇静药物采购成本高于其他两组(均P<0.001)。
  • 三组不良事件无显著差异(均P>0.05)。

证据类型、等级与局限

  • 证据类型:单中心随机对照研究。
  • 试验注册:NCT02528513,注册日期2015年8月19日。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,咪达唑仑序贯右美托咪定是长期镇静有效且安全的策略,可为特定危重机械通气患者提供有临床意义的获益。
  • 对于通过30分钟SBT但无拔管指征且仍需镇静的患者,可考虑将咪达唑仑更换为右美托咪定以缩短撤机时间并降低谵妄发生率。
  • 将咪达唑仑更换为丙泊酚也可缩短恢复、拔管和撤机时间,但镇静药物采购成本高于其他两组。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Current sedatives have different side effects in long-term sedation. The sequential use of midazolam and dexmedetomidine for prolonged sedation may have distinct advantages. We aimed to evaluate the efficacy and safety of the sequential use of midazolam and either dexmedetomidine or propofol, and the use of midazolam alone in selected critically ill, mechanically ventilated patients.

METHODS: This single-center, randomized controlled study was conducted in medical and surgical ICUs in a tertiary, academic medical center. Patients enrolled in this study were critically ill, mechanically ventilated adult patients receiving midazolam, with anticipated mechanical ventilation for ≥ 72 h. They passed the spontaneous breathing trial (SBT) safety screen, underwent a 30-min-SBT without indication for extubation and continued to require sedation. Patients were randomized into group M-D (midazolam was switched to dexmedetomidine), group M-P (midazolam was switched to propofol), and group M (sedation with midazolam alone), and sedatives were titrated to achieve the targeted sedation range (RASS - 2 to 0).

RESULTS: Total 252 patients were enrolled. Patients in group M-D had an earlier recovery, faster extubation, and more percentage of time at the target sedation level than those in group M-P and group M (all P < 0.001). They also experienced less weaning time (25.0 h vs. 49.0 h; HR1.47, 95% CI 1.05 to 2.06; P = 0.025), and a lower incidence of delirium (19.5% vs. 43.8%, P = 0.002) than patients in group M. Recovery (P < 0.001), extubation (P < 0.001), and weaning time (P = 0.048) in group M-P were shorter than in group M, while the acquisition cost of sedative drug was more expensive than other groups (both P < 0.001). There was no significant difference in adverse events among these groups (all P > 0.05).

CONCLUSIONS: The sequential use of midazolam and dexmedetomidine was an effective and safe sedation strategy for long-term sedation and could provide clinically relevant benefits for selected critically ill, mechanically ventilated patients.

TRIAL REGISTRATION: NCT02528513 . Registered August 19, 2015.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Zhou Y, Yang J, Wang B, et al. Sequential use of midazolam and dexmedetomidine for long-term sedation may reduce weaning time in selected critically ill, mechanically ventilated patients: a randomized controlled study. Crit Care. 2022. PMID: 35505432. doi:10.1186/s13054-022-03967-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。